Indication

GLP-1 medications for Type 2 diabetes

GLP-1 medications for Type 2 diabetes, with sourced prices, shortage reports and study results.

Last updated

Last checked · Nov 16, 2026 UTC
5approved
7in development

Approved for this use

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

Dulaglutide

Trulicity

FDA-approved for

  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $389/28 days (lilly.com/lillydirect/trulicity)

Trulicity single-dose pens · LillyDirect (Eli Lilly)

Checked on lilly.com

Price conditions

self-pay, four weekly pens; published starting rate at each dose

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Exenatide

Byetta (discontinued), Bydureon BCise (discontinued), Generic exenatide

FDA-approved for

  • Type 2 diabetes

Subcutaneous injection · Twice daily (Byetta); once weekly (Bydureon BCise)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

~$422 per pen (goodrx.com/exenatide)

Generic exenatide (Amneal) · GoodRx

Checked on goodrx.com

Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

Third-party reported price.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Liraglutide

Victoza, Saxenda

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once daily

FDA shortage reportIn shortage (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow · HealifyNow

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Semaglutide

Ozempic, Wegovy, Wegovy HD, Rybelsus

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) · Once weekly (injectable); once daily (oral)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Tirzepatide

Mounjaro, Zepbound

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Sleep apnea

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

Zepbound KwikPen via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Word for word

What each FDA label says about type 2 diabetes

From the indications section of each manufacturer's current label. A brand's wording decides who it is approved for.

  • Mounjaro: “as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.”FDA label, revised Aug 27, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Ozempic: “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”FDA label, revised Jun 1, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Rybelsus and Ozempic tablets: “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”FDA label, revised Jan 30, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Trulicity: “As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.”FDA label, revised Jun 16, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Victoza: “as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus,”FDA label, revised Oct 14, 2025 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed
Trulicity4.5 mg from week 13about 5 daysNo, it is a biologicNot in the Orange Book582,333

How long each takes · Generics and patents · Who covers what

Investigational (pipeline)

Alphabetical by active ingredient. These entries are not FDA-approved for this category; open a record for the studied uses and evidence.

Amycretin

Amycretin (investigational)

Studied for

  • Weight loss
  • Type 2 diabetes

Subcutaneous injection and oral tablet (both in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
GIP/GLP-1Phase 3

VK2735

VK2735 (investigational)

Studied for

  • Weight loss
  • Type 2 diabetes

Subcutaneous injection (oral tablet in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.